We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
3期SYNCHRONIZE-1分析:体重减轻13-16.6%,但因副作用停药率达19%。值得冒险吗?阅读完整评论。
新型双重激动剂Survodutide在无糖尿病的肥胖患者中实现了13%的体重减轻。了解该药物的作用机制、副作用及前景。